Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $20,500.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 2,500 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $8.20, for a total value of $20,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at approximately $989,699. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, November 11th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $7.82, for a total value of $19,550.00.
• On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.10, for a total value of $40,500.00.

Lexeo Therapeutics Trading Down 3.5 %

Shares of LXEO opened at $6.88 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $227.49 million and a P/E ratio of -2.18. The stock’s fifty day simple moving average is $8.09 and its 200 day simple moving average is $11.28. Lexeo Therapeutics, Inc. has a twelve month low of $5.77 and a twelve month high of $22.33.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LXEO shares. HC Wainwright increased their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Chardan Capital increased their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partners decreased their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $23.80.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Values First Advisors Inc. bought a new stake in Lexeo Therapeutics in the third quarter valued at about $67,000. Rhumbline Advisers increased its holdings in Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after buying an additional 3,627 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after purchasing an additional 7,803 shares during the last quarter. Finally, PDT Partners LLC bought a new position in shares of Lexeo Therapeutics during the third quarter valued at approximately $241,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.